Cytokinetics (CYTK) FDA Announcement summary

Introduction and purpose

• FDA approved Myqorzo (aficamten) for adults with symptomatic obstructive hypertrophic cardiomyopathy (OHCM/oHCM) to improve functional capacity and symptoms.

• The approval marks a significant milestone for patients and is the first FDA-approved medicine for the company.

• The announcement included details on the label, REMS, clinical data, and commercial launch plans.

Details of approval or decision

• Myqorzo is available as 5, 10, 15, and 20 mg tablets, with a flexible dosing regimen and no requirement for drug-drug interaction monitoring.

• Approval is based on positive results from the pivotal Phase 3 SEQUOIA-HCM trial.

• The product will be available in the U.S. in the second half of January 2026.

• Myqorzo is only available through a restricted REMS program due to heart failure risk, requiring prescriber and pharmacy certification, patient enrollment, and echo monitoring.

• The label includes a boxed warning for heart failure risk, mitigated by echo monitoring, and a single contraindication for rifampin.

Impact on industry and stakeholders

• Myqorzo is expected to achieve over 50% preference share in the cardiac myosin inhibitor (CMI) category and expand the market.

• The launch is supported by a comprehensive patient support program, including education and financial assistance.

• The approval is seen as a catalyst for broader adoption and increased access for patients and physicians.

• Patient advocacy groups highlight the approval as a long-awaited advancement.